A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial by Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, Alessandro Isidori, Peter te Boekhorst, Michael R. Savona, Prithviraj Bose, Olga Pozdnyakova, Ruben Mesa, Tarec C. El-Galaly, Jennifer O’Sullivan, Katia Gamel, Brian Higgins, Sudhakar Katakam, Boyan Todorov, Kerstin Trunzer, Claire N. Harrison

Get full text